Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;4(4):171-8.
doi: 10.1111/j.1750-2659.2010.00146.x.

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

P G Van Buynder  1 , J K Dhaliwal, J L Van Buynder, C Couturier, M Minville-Leblanc, R Garceau, F-W Tremblay
Affiliations

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

P G Van Buynder et al. Influenza Other Respir Viruses. 2010 Jul.

Abstract

Background: During the first wave of A/California/7/2009(H1N1) influenza, high rates of hospitalization in children under 5 years were seen in many countries. Subsequent policies for vaccinating children varied in both type of vaccine and number of doses. In Canada, children 36 months to <10 years received a single dose of 0.25 ml of the GSK adjuvanted vaccine (Arepanrix) equivalent to 1.9 microg HA. Children 6 months to 35 months received two doses as did those 36-119 months with chronic medical conditions.

Method: We conducted a community-based case-control vaccine effectiveness (VE) review of children under 10 years with influenza like illness who were tested for H1N1 infection at the central provincial laboratory. Laboratory-confirmed influenza was the primary outcome, and vaccination status the primary exposure to assess VE after a single 0.25-ml dose.

Results: If vaccination was designated to be effective after 14 days, no vaccinated child had laboratory-confirmed influenza compared to 38% of controls. The VE of 100% was statistically significant for children <10 years of age and <5 years considered separately. If vaccination was considered effective after 10 days, VE dropped to 96% overall but was statistically significant and over 90% in all age subgroups, including those under 36 months.

Conclusions: A single 0.25-ml dose of the GSK adjuvanted vaccine (Arepanrix) protects children against laboratory-confirmed pandemic influenza potentially avoiding any increased reactogenicity associated with second doses. Adjuvanted vaccines offer hope for improved seasonal vaccines in the future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Characteristics of Study Selection.
Figure 2
Figure 2
Number of positive pandemic influenza specimens and percent of immunized between 6 months to 9 years with H1N1 vaccine in New Brunswick, up to December 5, 2009. Data source: G. Dumont lab results and CSDS Immunization data.
Figure 3
Figure 3
Comparison of epidemiological curve for Canada and New Brunswick.
See this image and copyright information in PMC

References

    1. Baker MG, Kelly H, Wilson N Pandemic H1N1 influenza lessons from the southern hemisphere. Euro Surveill 2009;14(42): pii=19370. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19370. - PubMed
    1. New South Wales public health network . Progression and impact of the first winter wave of the 2009 pandemic H1N1 influenza in New South Wales, Australia. Euro Surveill 2009;14(42):pii=19365. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19365. - PubMed
    1. Smith S, Demicheli V, Di Pietrantonj C et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2006:CD004879 - PubMed
    1. http://www.gsk‐clinicalstudyregister.com/files/pdf/27868.pdf .
    1. http://www.gsk.ca/english/docs‐pdf/Arepanrix_PIL_CAPA01v01.pdf .